Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
MTNB Stock Forecast 2026-2027
$0.36
Current Price
$2.24M
Market Cap
Buy 0
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to MTNB Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
MTNB Price Momentum
-52.0%
1 Week Change
-49.3%
1 Month Change
-62.5%
1 Year Change
-39.0%
Year-to-Date Change
-88.5%
From 52W High of $3.09
+15.7%
From 52W Low of $0.31
📊 TOP ANALYST CALLS
Did MTNB Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Matinas BioPharma is one of their latest high-conviction picks.
Latest MTNB Stock Price Targets & Analyst Predictions
MTNB has shown a year-to-date change of -39.0% and a 1-year change of -62.5%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for MTNB. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MTNB Analyst Ratings
0
Buy
1
Hold
0
Sell
MTNB Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $0.36
Latest MTNB Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MTNB.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Oct 31, 2024 | Maxim Group | Hold | Downgrade | $N/A | |
| Oct 11, 2023 | BTIG | Julian Harrison | Buy | Reinstates | $3.00 |
| Jan 31, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Aug 13, 2020 | Aegis Capital | Buy | Maintains | $N/A | |
| Jan 27, 2020 | Piper Sandler | Overweight | Initiates | $N/A | |
| Jan 24, 2020 | SunTrust Robinson Humphrey | Buy | Initiates | $N/A | |
| Jun 26, 2019 | H.C. Wainwright | Buy | Initiates | $N/A | |
| Jun 26, 2019 | HC Wainwright & Co. | Buy | Initiates | $N/A | |
| May 17, 2019 | BTIG | Buy | Initiates | $N/A | |
| May 17, 2019 | BTIG Research | Buy | Initiates | $N/A | |
| Feb 11, 2019 | Roth Capital | Buy | Initiates | $N/A | |
| Nov 13, 2018 | Maxim Group | Buy | Maintains | $N/A | |
| Aug 13, 2018 | Maxim Group | Buy | Maintains | $N/A | |
| Jul 10, 2018 | Maxim Group | Buy | Maintains | $N/A | |
| Nov 1, 2016 | Aegis Capital | Buy | Initiates | $N/A |
Matinas Biopharma Holdings Inc. (MTNB) Competitors
The following stocks are similar to Matinas BioPharma based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Matinas Biopharma Holdings Inc. (MTNB) Financial Data
Matinas Biopharma Holdings Inc. has a market capitalization of $2.24M with a P/E ratio of -0.2x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -228.4%.
Valuation Metrics
Market Cap
$2.24M
Enterprise Value
$1.87M
P/E Ratio
-0.2x
PEG Ratio
0.0x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+104.9%
Current Ratio
1.3x
Debt/Equity
39.3x
ROE
-228.4%
ROA
-48.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Matinas Biopharma Holdings Inc. (MTNB) Business Model
About Matinas Biopharma Holdings Inc.
What They Do
Develops innovative therapeutics using lipid nano-crystal technology.
Business Model
Matinas Biopharma Holdings Inc. operates as a clinical-stage biopharmaceutical company that focuses on creating and advancing lipid nano-crystal delivery technology. This technology enhances the bioavailability and efficacy of pharmaceuticals, enabling better treatment options for infectious diseases and rare disorders. The company generates revenue through the development of novel therapeutics and potential partnerships with larger pharmaceutical firms.
Additional Information
The company's strategic focus on unmet medical needs positions it uniquely within the biotechnology sector, aiming to improve patient outcomes and accessibility to treatments. By optimizing drug exposure and safety profiles, Matinas Biopharma could significantly transform the administration of complex medications.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
2
CEO
Mr. Jerome D. Jabbour J.D.
Country
United States
IPO Year
2014
Website
www.matinasbiopharma.comMatinas Biopharma Holdings Inc. (MTNB) Latest News & Analysis
Latest News
Quick Summary
A new publicly traded company will focus on advanced clean energy, including modular carbon-free energy, green hydrogen, critical materials, and industrial decarbonization.
Why It Matters
The creation of a publicly traded clean energy company signals growth in sustainable sectors, attracting investment in green technologies and potentially boosting market valuations in these industries.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Matinas BioPharma Holdings, Inc. (NYSE: MTNB) received a notice of non-compliance from NYSE American due to insufficient stockholders' equity, impacting its continued listing status.
Why It Matters
Matinas BioPharma's non-compliance with NYSE listing standards raises concerns about its financial health and stability, potentially impacting its stock price and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards
3 months ago
Quick Summary
Matinas BioPharma (MTNB) received a notice from NYSE American for non-compliance with listing standards due to insufficient stockholders' equity, reporting $4.83 million amid ongoing losses.
Why It Matters
Matinas BioPharma's non-compliance with NYSE listing standards raises concerns about its financial health, potentially impacting stock value and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Matinas BioPharma Holdings, Inc. appointed Keith Murphy and Edward Neugeboren as independent board members, effective March 11, 2025.
Why It Matters
The appointment of experienced biotech veterans to Matinas BioPharma's board may enhance strategic direction and credibility, potentially leading to improved performance and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Matinas BioPharma Holdings, Inc. announced a securities purchase agreement for 3,300 shares of Series C Convertible Preferred Stock, raising $3.3 million from investors through this offering.
Why It Matters
Matinas BioPharma's $3.3 million capital raise through preferred stock and warrants signals financial support, impacting liquidity and potential growth, influencing investor sentiment and stock valuation.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Matinas BioPharma Holdings, Inc. appointed Evelyn D'An as an independent director and Chair of the Audit Committee, effective February 5, 2025.
Why It Matters
Evelyn D'An's appointment could enhance corporate governance and financial oversight at Matinas BioPharma, potentially boosting investor confidence and impacting stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About MTNB Stock
What is Matinas Biopharma Holdings Inc.'s (MTNB) stock forecast for 2027?
Analyst forecasts for Matinas Biopharma Holdings Inc. (MTNB) are not currently available. The stock is trading at $0.36.
Is MTNB stock a good investment in 2027?
According to current analyst ratings, MTNB has 0 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.36. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for MTNB stock?
Price predictions from Wall Street analysts for MTNB are not currently available. The stock is trading at $0.36.
What is Matinas Biopharma Holdings Inc.'s business model?
Matinas Biopharma Holdings Inc. operates as a clinical-stage biopharmaceutical company that focuses on creating and advancing lipid nano-crystal delivery technology. This technology enhances the bioavailability and efficacy of pharmaceuticals, enabling better treatment options for infectious diseases and rare disorders. The company generates revenue through the development of novel therapeutics and potential partnerships with larger pharmaceutical firms.
What is the highest forecasted price for MTNB Matinas Biopharma Holdings Inc.?
Price targets from Wall Street analysts for MTNB are not currently available. The stock is trading at $0.36.
What is the lowest forecasted price for MTNB Matinas Biopharma Holdings Inc.?
Price targets from Wall Street analysts for MTNB are not currently available. The stock is trading at $0.36.
What is the overall MTNB consensus from analysts for Matinas Biopharma Holdings Inc.?
The overall analyst consensus for MTNB is neutral. Out of 2 Wall Street analysts, 0 rate it as Buy, 1 as Hold, and 0 as Sell.
How accurate are MTNB stock price projections?
Stock price projections, including those for Matinas Biopharma Holdings Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 17, 2026 2:53 AM UTC